Aclaris Therapeutics
ACRS
107 hedge funds and large institutions have $62.4M invested in Aclaris Therapeutics in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 53 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
35% more call options, than puts
Call options by funds: $97K | Put options by funds: $72K
14.9% less ownership
Funds ownership: 98.84% → 83.94% (-15%)
22% less funds holding
Funds holding: 137 → 107 (-30)
55% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 53
87% less capital invested
Capital invested by funds: $480M → $62.4M (-$418M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$7.17M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$5.71M |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$5.37M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$48.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.8M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$30.1M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$19.2M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.6M |
ACRS Hedge Fund Activity: Q4 2023 in Review
107 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2023, worth a combined $62.4M — down 87% from $480M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of ACRS and 24 opened new positions — a net loss of 29 holders — while 26 trimmed existing stakes and 41 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $7.17M. The largest seller was BVF Inc, exiting entirely with an estimated $48.4M sold.
- 107 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2023, down from 137 in Q3 2023.
- Funds reported $62.4M of Aclaris Therapeutics stock for Q4 2023, down 87% quarter-over-quarter.
- 24 funds opened new Aclaris Therapeutics positions in Q4 2023 and 53 closed out, a net change of -29 holders.
- The largest Aclaris Therapeutics buyer in Q4 2023 was Acadian Asset Management, an estimated $7.17M added.
- The largest Aclaris Therapeutics seller in Q4 2023 was BVF Inc, an estimated $48.4M sold.
Based on aggregated 13F filings for Q4 2023.